Governance United Therapeutics Corporation

UTHR

US91307C1027

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 20:00:00 09/03/2026 GMT			5-day change	1st Jan Change
529.17 ^USD	+10.67%		+2.99%	+8.60%

03-09	United Therapeutics Corporation Presents at Leerink Global Healthcare Conference 2026, Mar-09-2026 01:00 PM
03-09	United Therapeutics Corporation authorizes a Buyback Plan.	CI

Executive Committee: United Therapeutics Corporation

Manager

Positions heldSince

Martine Rothblatt

71 year

Chief Executive Officer	25/06/1996
Founder	25/06/1996

Michael Benkowitz

54 year

Chief Operating Officer	25/06/2016
President	25/06/2016

Dewey Steadman

Investor Relations Contact	31/12/2018
Public Communications Contact	31/12/2018

Paul Mahon

62 year

General Counsel	25/06/1996
Corporate Secretary	25/06/1996

James Edgemond

58 year

Director of Finance/CFO	12/03/2015
Treasurer	31/12/2012

Composition of the Board of Directors: United Therapeutics Corporation

Director

CommitteesSince

Martine Rothblatt

71 year

Compensation Committee Chair

31/01/2021

Judy Olian

74 year

Audit Committee
Compensation Committee
Governance Committee	12/09/2018
Nominating Committee	30/04/2014
Executive Committee	12/09/2018
Compensation Committee Chair

Nilda Mesa

66 year

Compensation Committee	30/10/2018
Governance Committee	30/10/2018
Nominating Committee	30/10/2018

Louis Sullivan

92 year

Compensation Committee	06/03/2013
Governance Committee	06/03/2013
Nominating Committee	06/03/2013

Christopher Patusky

62 year

Governance Committee	23/10/2002
Nominating Committee	23/10/2002
Compensation Committee Chair	23/10/2002

Richard Giltner

62 year

Governance Committee	28/04/2009
Nominating Committee	28/04/2009
Audit Committee Chair	28/04/2009

Christopher Causey

63 year

Audit Committee	31/12/2002
Governance Committee Chair	08/08/2012
Nominating Committee Chair	08/08/2012

Linda Maxwell

52 year

Audit Committee	28/03/2021
Compensation Committee Chair	28/03/2021

Tommy Thompson

83 year

Audit Committee

Raymond Dwek

84 year

Compensation Committee

31/12/2001

Raymond Kurzweil

78 year

Executive Committee

Kevin Tracey

Director/Board Member

20/01/2026

Jan Malcolm

69 year

Director/Board Member	25/06/2024
Independent Dir/Board Member	25/06/2024

Latest Appointments: United Therapeutics Corporation

01-22	United Therapeutics Corporation Announces Appointment of Kevin J. Tracey to Board of Directors, Effective January 21, 2026	CI
01-07	SAB Biotherapeutics, Inc. Announces Board Changes ,Effective January 7, 2026	CI
27/06/24	United Therapeutics Corporation Announces Board Changes	CI
11/09/20	United Therapeutics Corporation Appoints Linda Maxwell to Its Board of Directors as an Independent Director	CI
01/11/18	United Therapeutics Corporation Appoints Nilda Mesa as an Independent Director	CI
28/04/16	United Therapeutics Corporation Announces Executive Leadership Changes, Effective June 26, 2016	CI
29/06/15	United Therapeutics Corporation Appoints Dean Judy D. Olian as Member of the Board	CI

More news

Former Officers and Directors: United Therapeutics Corporation

Insider

Positions held

SinceUntil

Katherine Klein

Director/Board Member	10/11/2014	25/06/2024
Independent Dir/Board Member	10/11/2014	25/06/2024

Andrew Fisher

Corporate Officer/Principal

31/12/2000

31/12/2017

Kiernan T. DeAngelis

Chief Tech/Sci/R&D Officer

31/01/2013

30/04/2017

Tracy Newbold

Chief Operating Officer

31/12/2010

31/12/2016

David Zaccardelli

Chief Operating Officer	31/12/2014	25/06/2016
Corporate Officer/Principal	31/12/2007	31/12/2014

Roger Jeffs

Director/Board Member	31/03/2001	25/06/2016
Chief Executive Officer	31/12/2014	25/06/2016
Chief Operating Officer	31/03/2001	31/12/2013
Chief Tech/Sci/R&D Officer	31/08/1998	31/03/2001
President	31/03/2001	25/06/2016

L. Smith

Corporate Officer/Principal

30/11/2014

31/05/2016

Scott Moomaw

Sales & Marketing

31/12/2010

30/04/2016

Alexander Sapir

Sales & Marketing

31/12/2005

30/04/2016

Jinky Ang Rosselli

Corporate Officer/Principal

30/04/2011

31/05/2015

John Maxim Ferrari

Comptroller/Controller/Auditor	30/04/2001	-
Director of Finance/CFO	30/04/2001	12/03/2015
Treasurer	30/04/2001	12/03/2015

Martin Auster

Corporate Officer/Principal

28/02/2009

30/04/2014

Eugene Jeffrey Sullivan

Chief Tech/Sci/R&D Officer

31/12/2006

31/12/2011

Robert Shorr

Chief Tech/Sci/R&D Officer

31/12/2004

Stuart Rich

Chief Tech/Sci/R&D Officer

30/09/2003

30/11/2004

Robert Paul Gray

Director/Board Member	31/12/2002	-
Independent Dir/Board Member	31/12/2002	-

Wayne I. Roe

Corporate Officer/Principal

31/10/1999

31/10/2000

David Green

Director/Board Member

Ricardo Balda

Director/Board Member

Robert F. Roscigno

Director/Board Member	-	-
Corporate Officer/Principal	-	-

Peter L. Ginsberg

Corporate Officer/Principal

Matthew M. Seavey

Corporate Officer/Principal

Carl Sterritt

Corporate Officer/Principal

Tessio Rebello

Chief Tech/Sci/R&D Officer	15/07/2009	15/07/2009
Corporate Officer/Principal	21/05/2009	15/07/2009
President	-	21/05/2009

Bill Cook

Corporate Officer/Principal

David Walsh

Corporate Officer/Principal

Henry Hicks

Director/Board Member

Fred T. Hadeed

Corporate Officer/Principal

Age distribution of managers

Parity Men Women

Male	15
Female	2

Of which Executive Committee

Male	5
Female	0

Of which Directors

Male	11
Female	2

Revisions

Recommandations analystes

Évolution recommandations analystes 1 an

Évolution recommandations analystes 4 mois

Objectif analystes

Évolution objectif analystes 1 an

Évolution objectif analystes 4 mois

ESG MSCI

Environnement

Social

Gouvernance

Polémique

Controverses Ethiques

Controverses sur les droits de l'Homme

Controverses Subventions fiscales

Conforme à la finance Islamique

United Therapeutics Corporation is a pharmaceutical company. It markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection (Unituxin) for treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin (Remunity). Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKindâ€™s Afrezza (insulin human) Inhalation Powder.

Employees

1,400

Sector

Pharmaceuticals

More about the company